Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors.

After CI therapy, long-surviving advanced melanoma patients commonly report fatigue but otherwise have moderate symptom burden and good QOL. Ensuring appropriate symptom management will optimize clinical outcomes for these patients.